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Emerging strategies in cancer therapeutics link the genomic mutational and proteomic landscape, allowing
intelligent reasoning on target selection. In this issue of Cancer Cell, Piccinin and colleagues use this
approach to demonstrate that the mesenchymal protein Twist1 inhibits p53, providing a novel target for
reactivation of p53 in human sarcoma.One of the fundamental aims in biomed-
ical research is the discovery of protein-
protein interactions. This has led to an
information explosion on biological
pathway function, protein-networks, and
signaling hubs. In the case of p53, this
knowledge is beginning to be translated
into cancer patient stratification that
complements the advances already being
made using gene mutation status and
transcription profiling to predict thera-
peutic responses (Burington et al., 2011).
Over 30 years of research has led to
over 400 interacting proteins described
for p53 that have driven exciting
advances in drug development programs
that target p53 inhibitors, like ubiquitin
ligases (MDM2), histone de-acetylases
(SIRT1 and SIRT2), and protein kinases
(Aurora, CK1, and CDK; Figure 1). One
of the key aims of translational biomedi-
cine is to link this vast information on
p53 interactors into clinically relevant
cancer therapeutics. In this issue of
Cancer Cell, Piccinin et al. (2012) bridge
this gap and demonstrate that the
mesenchymal signaling protein Twist1
forms a clinically relevant inhibitory p53
interaction in human sarcoma.
Our understanding of the genetics of
human sarcoma has been facilitated by
improved molecular classification using
next generation sequencing technologies
(Barretina et al., 2010), which has
impacted clinically relevant target choice
and in rational use of small molecules
targeting kinases through to monoclonal
antibodies targeting receptors for treat-
ing sarcoma (Figure 1). In the case of the
most well studied p53 inhibitor of all,
MDM2, next generation technologies
have shown that MDM2 is one of the keygenes often amplified in human sarcoma
(Taylor et al., 2011). Emerging trans-
lational data also demonstrate that
melanomas overproducing the MDM2
homolog MDM4 form clinical settings in
which to apply targeted therapeutics
(Gembarska et al., 2012). In human
sarcoma, the ratio of spliced MDM4 full-
length and smaller isoforms better
defined patients with poor survival rates
than the mutation status of p53 (Lenos
et al., 2012). This affirmation of MDM2 or
MDM4 activation in human sarcoma
provides a compelling clinical setting to
investigate the potential targeting of
these relatively well-characterized p53
pathway inhibitors. Current compounds
targeting MDM2 protein range from lead
molecules interacting with its hydro-
phobic peptide binding pocket (Vassilev
et al., 2004) to the use of conformationally
constrained peptides (e.g., stapled pep-
tides), which offers enormous potential
to develop a new generation of protein-
protein interaction inhibitors to be evalu-
ated clinically (Crunkhorn, 2011). There-
fore, there is a significant potential to
stratify patients in sarcoma clinical trials
that might benefit from MDM2 or MDM4
targeted therapeutics.
Despite this enormous promise in
targeting MDM2 to reactivate p53, human
sarcomas are a very heterogeneous
group of cancers arising from mesen-
chymal tissues within fat, muscle, periph-
eral nerves, fibrous tissue, or bone, and
the wt-p53 alleles are not always retained.
Even in sarcomas with wt-p53 alleles,
MDM2 is not always the dominantly
expressed p53 suppressor, and identifi-
cation of such clinically relevant p53-
inhibitors is a prime goal. Piccinin et al.Cancer Cell 22, Se(2012) identify such a dominant pro-
oncogenic inhibitory protein interaction
between Twist1 and the C terminus of
p53. Targeting the Twist1-p53 complex
not only provides a novel, clinically rele-
vant approach for reactivating p53, but
it also complements the existing poten-
tial to target synergistically other p53
inhibitory pathways. This knowledge
will hopefully give momentum to strategi-
cally choose approaches to reactivate
p53 in sarcomas by targeting these
oncogenic protein-protein interaction
networks (Figure 1).
Our limited knowledge of oncogenic
protein-protein interactions driving sar-
coma, such as Twist1-p53 or MDM2-
p53, contrasts with our understanding
using genomics that has divided this
cancer into two types. Group I sarcomas
have near-diploid karyotypes but harbor
specific chromosomal translocations,
most of which encode chimeric tran-
scription fusion proteins. For example,
the PAX3-FOXO1 chimera in alveolar
rhabdomyosarcoma reveals how mesen-
chymal developmental pathways can be
exploited by evolving cancers. There
are over a dozen other chimeric tran-
scription factors that reveal the genetic
diversity of these sarcomas groups.
Group II sarcomas are characterized
by unbalanced karyotypes reflecting
genome instability and mutations in p53
that result in genomic heterogeneity
across tumor types. This heterogeneity
is highlighted by recent whole-genome
sequencing showing that some oste-
osarcomas and chordomas evolve
through a mechanism called chromo-
thripsis (Stephens et al., 2011), reflecting
evolution from a single ‘‘catastrophic’’ptember 11, 2012 ª2012 Elsevier Inc. 283
Figure 1. Therapeutic Targets in Human Sarcoma
In human sarcoma, some of the receptor-mediated regulatory pathways that have been identified as
therapeutic targets include VEGFR, IGF-R1, PDGFR, and EGFR, which form the focus for monoclonal
antibody-based approaches. Similarly, enzymes such as receptor tyrosine kinase growth factors or
CDK4 gene amplification highlight the potential for targeted kinase inhibitors. A subset of human
sarcomas expressing wild-type p53 form clusters that might be targeted with p53-activating therapeutic
molecules. The p53-inhibitory pathways whose components currently have small molecule drug leads
include: (1) degradation pathways comprising MDM2, with its cofactors CK1a and MDM4; (2) unfolding
and destabilization of the p53 core domain by the mitotic Aurora kinase family; (3) export pathways
comprising the kinase GSK3 or the nuclear receptor CRM1; (4) transcription sensing pathways composed
of kinases that regulate Pol-II transcription like CDK2/CDK9 and chromatin remodelling factors like the
Sirtuins; and (5) p53 ‘‘activation’’ inhibitors epitomized by Twist1 that block a specific p53 activation
phosphorylation. Exploiting the Twist1-p53 interface forms a novel approach for stimulating wt-p53 in
certain mesenchymal cancers.
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one chromosome.
In order to discover clinically relevant
oncogenic drivers in human sarcoma,
Piccinin et al. (2012) reasoned that Group
I sarcomas containing the near-diploid
karyotype often retain wt-p53 alleles,
suggestive of oncogenic pathways that
suppress p53 and bypass p53 gene
mutation as a selective advantage in
cancer development. In order to identify
the physiological factors that might
attenuate wt-p53 in sarcoma, one likely
source would be developmentally pro-
grammed pathways, which are intrinsic
to mesenchymal tissue, such as Twist1.
The Twist1 bHLH transcription factor is
involved in tissue speciation following
mesoderm induction specifically during
embryogenesis and plays a role in
metastatic signaling through induction of284 Cancer Cell 22, September 11, 2012 ª20EMT, and Twist1 signaling was previously
implicated in silencing ARF-mediated
oncogene activation of p53. The authors
thus examined the mechanism whereby
Twist1 might attenuate wt-p53 functions
in mesenchymal-derived cancers. The
authors show that Twist1 binds to
the intrinsically disordered motif in the
C-terminal regulatory domain of p53,
a region that contains the majority of
binding sites for p53-interacting proteins
as well as covalent modification sites
including phosphorylation, ubiquitin-like
modification, and acetylation. Twist1
binding specifically attenuates an acti-
vating phosphorylation at Ser392 (CK2/
FACT phosphorylation motif) implicated
normally in stimulating DNA-damage
activated gene expression (Bruins et al.,
2008). This hypophosphorylated p53
becomes sensitized to degradation by12 Elsevier Inc.an MDM2-dependent pathway, although
the contribution of the other known p53
ubiquitin ligases, such as PirH2 or
TRIM28, cannot be ruled out.
The Twist1 interaction with p53
provides another example of the now
hundreds of p53 protein-protein interac-
tions. One of the main difficulties in ex-
ploiting this vast knowledge of p53 for
improving therapeutic strategies to treat
cancer is that the clinical penetrance of
most of these protein-protein interactions
has not yet been defined. A key insight
developed by Piccinin et al. (2012) at the
outset was to define clinical settings
where this inhibitory Twist1-p53 interac-
tion might be clinically important to
increase probability of having a future
impact for patients. Over 140 human
sarcomas of a large range of subtypes
were screened for Twist1 expression,
and over 60% exhibited strong nuclear
protein expression, which in a fraction of
cancers can be explained by a copy
number gain. Liposarcoma and leiomyo-
sarcoma were the types with highest
percentages of Twist1 overexpression.
Further, in leiomyosarcomas, there was
an inverse correlation between Twist1
protein expression and p53 gene muta-
tion. These data together suggest that
there are at least two distinct pathways
that drive the evolution of these sarcomas
with either mutant p53 or wt-p53 and
that high or low expression of Twist1
might play a role in driving these diverse
evolutionary paths.
Genomics and proteomics platforms
are now allowing annotation of clinically
dominant pro-oncogenic driver muta-
tions, gene expression profiling, protein-
protein interactions, and potential drug
targets with clinical relevance. Identifying
clinical niches for such drug targets
facilitates the a priori stratification of
patients that might benefit from a specific
therapy. However, the heterogeneity in
human cancer is vast, highlighted by the
diversity of sarcoma subtypes. To achieve
such rational targeted therapeutics will
require highly focused and integrated
interdisciplinary collaborative research
networks that drive patient stratification
using molecular pathology, target choice,
drug development, pharmaceutical
engagement, and clinical trials. Some of
the therapeutic possibilities in human
sarcoma include using the currently
available lead molecules targeting protein
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bodies targeting receptors like IGF-R1 or
EGFR, and peptide-mimetic MDM2
protein-interaction inhibitors that can
rescue wt-p53 functions (Figure 1). We
can now include the clinically relevant
p53 protein interaction from Twist1 as
a key target to evaluate for its therapeutic
potential. There is enormous promise in
drugging such protein-protein interac-
tions, as this forms an untapped and
large landscape for drug development
(Crunkhorn, 2011).
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The first two murine models of IDH1(R132H) mutation provide mechanistic insights into transformation. In
hematopoietic cells, inhibition of TET2 and histone demethylases leads to epigenetic alterations and accu-
mulation of hematopoietic precursors. In the central nervous system, inhibition of collagen and prolyl hydrox-
ylases lead to altered microenvironment and defective angiogenesis.Large-scale sequencing efforts have iden-
tified novel genes that are somatically
mutated in cancer. Two of the more unex-
pected genes that have been implicated
as recurrent mutational targets are IDH1
and IDH2, which encode isocitrate dehy-
drogenase-1 and isocitrate dehydroge-
nase-2, respectively. These enzymes
catalyze the conversion of isocitrate to
a-ketoglutarate (aKG) in anNADP+depen-
dent manner. Mutations in IDH1 were first
identified in colorectal cancer, and later,
mutations in IDH1/IDH2 were identified in
brain tumors, with >70% incidence in
secondary gliomas (Yan et al., 2009).
Through whole-genome sequencing of
a case of acute myeloid leukemia (AML),
an IDH1 mutation was identified, and
IDH1/IDH2 mutations were subsequently
found in 12%–18% of AML cases (Mardis
et al., 2009). Mutations have also beenidentified in thyroid cancers, chondrosar-
comas, and cholangiocarcinomas.
At first it was puzzling how basic meta-
bolic enzymes could be linked to cancer.
The mutant IDH1/IDH2 enzymes have
decreased enzymatic activity known at
that time. However, the observations
that the mutations always presented as
heterozygous and at highly conserved
arginine residues are more consistent
with these being gain-of-function. This
led to the critical finding that these
mutants acquired neomorphic activity
converting aKG to 2-hydroxyglutarate
(2HG) (Dang et al., 2009; Ward et al.,
2010). Tumor samples harboring these
mutations had 2HG at levels up to 100-
fold greater than controls. Besides being
an intermediate in the Krebs cycle, aKG
is involved in other biochemical pro-
cesses, including synthesis of glutamate,transamination of amino acids, generation
of NADPH, and acting as a cofactor for
dioxygenase enzymes. The structural
similarity between 2HG and aKG sug-
gested that other enzymatic processes
maybecompetitively inhibitedbyelevated
2HG levels (Xu et al., 2011) (Figure 1).
Through analysis of global DNAmethyl-
ation profiles in glioblastomas (GBMs),
a distinct profile termed CpG island meth-
ylator phenotype with elevated genomic
methylation was found to be closely asso-
ciated with IDH1 mutations (Noushmehr
et al., 2010). Subsequently, it was discov-
ered that IDH1/IDH2 mutations were
mutually exclusive with TET2 mutations,
a gene encoding an aKG-dependent
enzyme involved in DNA demethylation,
suggesting that these proteins are in-
volved in the same pathway. Biologic
significance was demonstrated throughptember 11, 2012 ª2012 Elsevier Inc. 285
